Syncromune® Inc. Presents Positive Results from SYNC-T™ Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancerFinal clinical data demonstrate an 87% overall response rate in patients with metastatic prostate cancerResults support...